Status
Conditions
Treatments
About
Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance.
Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age:20-40 years old
BMI:20-40kg/m
Normal baseline hormonal profile (on the 2nd day of the cycle)
No Endometriosis by laparoscopy
No prior ovarian surgery; overectomy, ovariectomy or oophrectomy
Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy
Exclusion criteria
Age: <20 or >40 years old 2. BMI: <20 or >40kg/m 3. Female subjects with any contraindication for pregnancy. 4. Female subjects with history of tumors of the hypothalamus & pituitary gland.
Female subjects with history of ovarian, uterine or mammary cancer. 6. Female subjects with history of hypersensitivity to the active substance of the medications used for ovarian stimulation.
Abnormal baseline hormonal profile 8. Endometriosis by laparoscopy 9. Previous ovarian surgery; overectomy, ovariectomy or oophrectomy 10. Female subjects with abnormal gynecological bleeding of unknown etiology
Loading...
Central trial contact
Ahmed M Selim, MBBCh
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal